In the absence of approved therapy, physicians mostly attempt to treat the pain of Chemotherapy-Induced Peripheral Neuropathy with oral antidepressants and anti-epileptics. After several weeks of treatment, those medicines can achieve limited pain reduction in some patients but tend to cause various side-effects : cardiovascular, neurological, psychological, neuromuscular or anticholinergic are the more frequent ones.
ATX01 is a First-in-Class topical treatment for peripheral neuropathic pain. Its development focus is on the pain of Chemotherapy-Induced Peripheral Neuropathy and erythromelalgia. ATX01’s pharmacological paradigm is that it directly targets the epidermis and dermis – where the damaged nerve fibers sit – and avoids significant systemic absorption and its cascade of side-effects.
« ACT » (ATX01 against the pain of ChemoTherapy) is a Phase 2, multicenter, double-blind, placebo-controlled 2 study currently enrolling 240 patients in the US and Europe. In Q2 2023, the « EASE » study (Efficacy of ATX01: Study in Erythromelalgia) will explore the efficacy of ATX01 to relieve the pain of Erythromelalgia, a rare and extremely painful condition.